SEC Form 4 · accession 0001209191-18-047221
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gad Soffer
Officer — EVP & Chief Strategy Officer
Period of report
Aug 15, 2018
Accepted (ET)
Aug 16, 2018 · 8:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2018 | F | 382 | $35.90 | D | 266,124 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to cover tax obligation from settlement of vested restricted stock units.